2010 - Lasofoxifene reduced vertebral fractures in postmenopausal women with osteoporosis

Crandall, Carolyn J.
July 2010
ACP Journal Club;7/20/2010, Vol. 153 Issue 1, p10
Academic Journal
The article offers the author's views on a research study which finds that lasofoxifene reduces risk for vertebral fractures in post postmenopausal women with osteoporosis. The author says that in the last five years, 161 women with osteoporosis needed to undergo lasofoxifene therapy. However, to become lasofoxifene therapy widely available clinicians would require to first determine whether lasofoxifene should be used to treat osteoporosis or to decrease breast cancer risk.


Related Articles

  • INDEPENDENT NURSING ACTIONS-INSTRUMENT TESTING. Eilers, June; Heermann, Judy; Wilson, Margaret; Million, Rita // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p242 

    In cooperative care, nurses partner with lay caregivers who assume responsibility for 24 hour care of the transplant recipient in an acute care setting. Preparation of these lay carepartners to assume care responsibilities is a key nursing intervention. Identification of independent nursing...

  • PREDICTING LIKELIHOOD OF MULTIPLE FALLS IN POSTMENO-PAUSAL BREAST CANCER SURVIVORS (BCSs) WITH LOW BONE MINERAL DENSITY. Waltman, Nancy; Ott, Carol; Twiss, Janice; Gross, Gloria; Lindsey, Ada; Berg, Kris // Oncology Nursing Forum;Jan2007, Vol. 34 Issue 1, p181 

    Breast Cancer Survivors (BCS) are at risk for osteoporosis because treatments can cause early- onset menopause and loss of bone mineral density (BMD). Consequences of osteoporosis are fractures, often precipitated by falls. To prevent fractures, BCS with low BMD at risk for falls should be...

  • Calcium channel blocker use may be linked to breast cancer.  // Reactions Weekly;8/10/2013, Issue 1465, p1 

    The article presents a case-control study which examines the correlation of long-term use of calcium-channel blockers (CCBs) with an increased risk of breast cancer among postmenopausal women.

  • Update in Hematology and Oncology: Evidence Published in 2010. Schilsky, Richard L.; Crowther, Mark // Annals of Internal Medicine;4/5/2011, Vol. 154 Issue 7, p487 

    The article reviews several articles related to hematology and oncology including "Oral bisphosphonate use and breast cancer incidence in postmenopausal women," by R. T. Chlebowski and colleagues, "Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient...

  • A phase-III prevention trial of low-dose tamoxifen in postmenopausal hormone replacement therapy users: the HOT study. DeCensi, A.; Bonanni, B.; Maisonneuve, P.; Serrano, D.; Omodei, U.; Varricchio, C.; Cazzaniga, M.; Lazzeroni, M.; Rotmensz, N.; Santillo, B.; Sideri, M.; Cassano, E.; Belloni, C.; Muraca, M.; Segnan, N.; Masullo, P.; Costa, A.; Monti, N.; Vella, A.; Bisanti, L. // Annals of Oncology;Nov2013, Vol. 24 Issue 11, p2753 

    Background Postmenopausal hormone replacement therapy (HRT) relieves menopausal symptoms and may decrease mortality in recently postmenopausal women, but increases breast cancer risk. Low-dose tamoxifen has shown retained activity in phase-II studies. Methods We conducted a phase-III trial in...

  • ERT lowers breast-cancer risk?  // Consumer Reports on Health;Oct96, Vol. 8 Issue 10, p113 

    Reports that estrogen replacement therapy (ERT) decreases breast cancer risks in post-menopausal women.

  • More carotenoids may lower breast cancer risk.  // Women's Nutrition Connection;Mar2013, Vol. 16 Issue 3, p1 

    The article reports on the study published in the December 6, 2012 issue of the "Journal of the National Cancer Institute" which revealed that carotenoids may lower the risk of breast cancer in the U.S.

  • Breast cancer incidence dropped sharply after patients stopped estrogen with progestin therapy.  // Hem/Onc Today;1/10/2009, Vol. 10 Issue 1, p22 

    The article presents findings of a study on the role of stopping estrogen with progestin therapy in reducing the risk for breast cancer in postmenopausal women.

  • PEARL: Lasofoxifene reduced incidence of total breast cancer by 79%.  // Hem/Onc Today;12/10/2010, Vol. 11 Issue 23, p68 

    The article focuses on the Postmenopausal Evaluation and Risk-Reduction with Lasofoxifene (PEARL) trial which shows that post menopausal women who took lasofoxifene experienced a decline in the risk for total breast cancer by 79% and risk for estrogen-receptor (ER)-positive invasive disease by 89%.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics